Rapport Therapeutics Inc.

This phase 3 study tests whether an investigational drug called RAP-219 can safely reduce the number of focal seizures in adults with epilepsy. About 312 participants will take either a low or medium dose of RAP-219 or a placebo pill daily. The main goal is to see if the drug low…

This study tests an experimental drug called RAP-219 in 333 adults with focal seizures (a type of epilepsy). The goal is to see if the drug safely reduces how often seizures happen compared to a placebo. Participants must be 18-75, have had focal epilepsy for at least 2 years, an…

This study tests the long-term safety of an experimental drug called RAP-219 in 30 adults whose focal seizures do not respond well to current treatments. Participants must have already completed a related earlier study. The goal is to see if RAP-219 remains safe and helps reduce …

This study tests an experimental drug called RAP-219 for people with bipolar I disorder who are currently experiencing a manic episode. About 250 participants will receive either RAP-219 or a placebo daily for 21 days. Researchers will measure changes in manic symptoms using a st…